AUG. 17. 2004 11:43AM NO. 6496 AVENTIS US PAT DEPT P. 1 FAX TRANSMITTAL TO THE UNITED STATES PATENT OFFICE AUG 1 7 2004 Applicants Docket Number: FRAV2003/0009 US NP TIFICATE OF TRANSMISSION I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1430, Missing Parts, at 703-746-4060, on Date of Deposit Alignst 17, 2004 Applicants: GUILLAUME, et al. Printed Name on Signing Certificate Jonas Pierre, Sr. Serial No. Signature 10/823,142 Total Number of Pages Sent: Filing Date: Attorney: Joel B. German April 13, 2004 Reg. No. 48,676 Group Art Unit: Not Yet Known Title of Invention: Examiner: Not Yet Known METHOD FOR OBTAINING MASTOCYTE LINES FROM PIG TISSUES AND FOR PRODUCING HEPARIN-TYPE MOLECULES TO: Mail Stop Missing Parts Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

$\boxtimes$	Reply to Notice to File Missing Parts of Nonprovisional Application		Fee Transmittal	
$\boxtimes$	Declaration (2 pages)		Petition under 37 CFR	
$\boxtimes$	Power of Attorney (1 page)		Other	
$\boxtimes$	Copy of Notice (2 pages)		Other	
	Transmittal (3 pages)			
				- ALLENS
Danai	nt Confirmed.			
VCCCI	Receipt Confirmed:			

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the centre of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

AUG 1 7 2004

TRADEN

V

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of GUILLAUME, et al.

Application No.: 10/823,142

Filed:

April 13, 2004

Title:

METHOD FOR OBTAINING MASTOCYTE LINES FROM PIG TISSUES AND FOR PRODUCING HEPARIN-TYPE MOLECULES Examiner: Not Yet Known

Art Unit:

Not Yet Known

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted with far-simile to the Commissioner for Patents, Alexandria, VA-22312, on

Date of Transmission

Jonas Pierre, Sr.

# REPLY TO NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

Mail Stop Missing Parts Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sirs:

In response to the "Notice to File Missing Parts of Nonprovisional Application", which was mailed August 10, 2004, and which indicated that the Oath or Declaration was unsigned. Applicants submit herewith the Declaration for the present application. In addition, applicants submit herewith the Power of Attorney for the present application.

Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account No. 18-1982. Two (2) duplicate copies of this sheet are enclosed.

Respectfully submitted,

Joel B. German, Reg. No., 48,676 Automey/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0009 US NP

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

APPLICATION NUMBER

UNITED STATES DEFAULT AND TRACEMENT UNITED STATES PATENTS AND PATENTS inia 22313-1450

10/823,142

BRIDGEWATER, NJ 08807

FILING OR 371 (c) DATE 04/13/2004

FIRST NAMED APPLICANT Jean-Marc Guillaume

ATTORNEY DOCKET NUMBER

FRAV2003/0009 US NE

Date Mailed: 08/10/2004

005487 ROSS J. OEHLER AVENTIS PHARMACEUTICALS INC. **ROUTE 202-206** MAIL CODE: D303A

**CONFIRMATION NO. 4542 FORMALITIES LETTER** 

\*OC000000013491110\*



### NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

### Items Required To Avoid Abandonment;

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The path or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

The application is informal since it does not comply with the regulations for the reason(s) Indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment.

- A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125, is required. The specification, claims, or abstract page(s) submitted is not acceptable and cannot be scanned or properly stored because:
  - The line spacing on the specification, claims, or abstract is not 1½ or double spaced (see 37 CFR 1.52(b)).
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37

10823142 08/18/2004 SSESHE1 00000052 181982

130.00

PAGE 5/9 \* RCVD AT 8/17/2004 11:38:47 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-4/1 \* DNIS:7464060 \* CSID:908 231 2626 \* DURATION (mm-ss):02-40

CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

#### SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is \$130 for a Large Entity

\$130 Late oath or declaration Surcharge.

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.

Customer Service Genter

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE